AzTrials
AzTrials

Pacing-Induced CardiomyopathyNCT06100757

Effect of Leadless Pacing on Heart Function

A study testing Micra Transcatheter Pacing System (TPS° and Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR in people with Pacing-Induced Cardiomyopathy, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This prospective, un-blinded, randomized, noninferiority, single centre study with 12 month follow-up included patients who were scheduled for a single-chamber PM implant. Patients were 1:1 randomized to undergo the implantation of a conventional VVI pacing system (Medtronic, Advisa ADSR03) with a ventricular pacing… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pacing-Induced Cardiomyopathy
What is being tested?
Micra Transcatheter Pacing System (TPS° and Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
51 participants
Where
1 siteBelgium
Study dates
1 May 2018to 31 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with a Class I or II indication for single chamber pacemaker following international guidelines

Who cannot join

  • patients with previously implanted cardiac devices / mechanical valves that would interfere with the echocardiographic measurements
  • patients with inadequate image quality at baseline that prohibited the assessment of myocardial mechanics using echocardiography
  • patients with a left ventricular ejection fraction (LVEF) ≤40% at baseline
  • patients considered to have a pre-existing condition challenging/precluding the implant of a conventional pacemaker
  • patients who refused or were not able to provide written informed consent.

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • University Hospitals of Leuven

    Leuven, 3000

Other trials in Belgium

About this study

Official title: Ventricular Mechanical Impact, Contraction Efficiency and Heart Function With Right Ventricular Pacing by MICRATMTPS. Comparison With Conventional RV Pacing

This prospective, un-blinded, randomized, noninferiority, single centre study with 12 month follow-up included patients who were scheduled for a single-chamber PM implant. Patients were 1:1 randomized to undergo the implantation of a conventional VVI pacing system (Medtronic, Advisa ADSR03) with a ventricular pacing lead (Medtronic, 5076-58) in the right ventricle (called 'conventional group') or to be implanted with a leadless Micra TPS (called 'Micra group').

The primary objective was to assess and compare the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function.

Read the detailed description

The primary endpoint was to assess the mechanical impact of the Micra TPS on the left ventricular function. The investigators measured the change of Global Longitudinal Strain (GLS) over one year after pacemaker implantation.

As secondary endpoint, the investigators studied the effect of the Micra TPS on the right ventricle using speckle tracking for 2-D myocardial motion estimation. The investigators also assessed conventionally the function of the right ventricle using tricuspid annular plane systolic excursion (TAPSE) in accordance with the guidelines of the European Association of Cardiovascular Imaging and American Society of Echocardiography. Evolution of clinical and biological parameters as NYHA (New York Heart Association) classification, '6 minutes 'walk distance and measurement of brain natriuretic peptide (NT-proBNP) test was also be performed at baseline and after one year follow-up.

Design

It was an interventional prospective not blinded randomized single centre study. The investigators randomized fifty patients into two groups (1:1 ratio) between May 2018 and December 2021:

Group 1 : 25 patients underwent the implantation of a conventional ventricular pacemaker (Medtronic) with placement of a ventricular lead Medtronic 5076-58 in the right ventricle.

Group 2 : 25 patients underwent the implantation of a leadless pacing system Micra TPS.

All implantation procedures were performed under local anaesthesia. To minimize the impact of the pacing site, the investigators targeted as first position the mid septum of the right ventricle. In the presence of inacceptable electrical measurements, an apical positioning was reached. All pacing positions were reviewed according to the Lieberman criteria.

Patients follow-up Patients were followed for a minimal period of 1 year (at 1 month after implantation, 6 months and 12 months as in routine care). Two-dimensional echocardiography was performed 1 day before implantation and at each visit. A 6 minutes' walk distance was performed at day 10 and at 1 year follow-up. As biological marker of the left ventricular function, brain natriuretic peptide (NT-proBNP) was also measured at baseline and at 1 year follow-up.

Device data collections:

The implant procedure duration as the procedure fluoroscopy times were also recorded. Follow-up of the electrical measurements was performed at the same time than the echocardiographic recording.

All complications (implantation failure, device or lead dislodgements, implantation related infection, death) were also prospectively documented.

Conventional 2D-Echocardiography:

Transthoracic echocardiography was performed using a commercially available ultrasound machine (VividTM E95, GE Vingmed Ultrasound AS; Epiq, Philips Medical Systems). Baseline and follow-up echocardiographic examinations were performed using the same machine. Conventional echocardiographic data were analysed according to the recommendations of the European Association of Cardiovascular Imaging. Standard parasternal long- and short-axis and apical four and two-chamber and long axis view were acquired. Left ventricular end-diastolic volume (LVEDV), end-systolic volume (LVESV) and left ventricular ejection fraction were calculated using Simpson's rule in a four-chamber view.

The ystolic function of the right ventricle was evaluated by tricuspid annular plane systolic excursion (TAPSE) in a standard apical four-chamber view. Finally, valve function and particularly tricuspid function was assessed following the European recommendations.

All echocardiographic values will be obtained from the average of measurements from six continuous normal cardiac beats.

Ethical considerations:

The investigators followed the declaration of Helsinki regarding human experimentation. Moreover, the investigators respected national legislation regarding clinical research and confidentiality of the data obtained in this study. All the participants were informed about the aims and procedures of the study and signed an informed consent form before the inclusion in the study. The local ethical committees reviewed and approved this protocol.

Being tested
Micra Transcatheter Pacing System (TPS°, Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR
Keywords
leadless pacemaker, Micra Transcatheter pacemaker, ventricular function, valve function

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Micra Transcatheter Pacing System (TPS°Device

    Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months

  • Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VRDevice

    Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months

Study groups in NCT06100757
Study groupRoleWhat they receive
Conventional pacingActive comparator24 patients underwent the implantation of a conventional VVI pacing system (Medtronic) with placement of a ventricular pacing lead Medtronic 5076-58 in the right ventricle.
Receives: Device: Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR
leadless pacingExperimental27 patients underwent the implantation of a leadless pacing system Micra TPS
Receives: Device: Micra Transcatheter Pacing System (TPS°

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment and comparison of the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function.

    The primary endpoints were the change in left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS)

    Measured: 1 year

Secondary outcomes (3)
  1. Evolution of the right ventricular, tricuspid valve and mitral valve function

    Echocardiographic measurements at baseline and 1-year follow-up

    Measured: 1 year

  2. Evolution of NT-pro-BNP

    Measurement of NT-pro BNP at baseline and 1-year follow-up

    Measured: 1 year

  3. Evolution of pacemaker performance

    Measurement of electrical parameters: pacing threshold, impedance and R-wave sensing. Measurement of percentage of ventricular pacing in both groups.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Oct 2023
  2. Study start1 May 2018
  3. Primary completion30 Nov 2021
  4. Study completion31 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
51 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06100757
Sponsor's protocol ID
S59717
Status last verified
Oct 2023
First submitted
20 Oct 2023
Last updated
31 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Garweg C, Duchenne J, Vandenberk B, Mao Y, Ector J, Haemers P, Poels P, Voigt JU, Willems R. Evolution of ventricular and valve function in patients with right ventricular pacing - A randomized controlled trial comparing leadless and conventional pacing. Pacing Clin Electrophysiol. 2023 Dec;46(12):1455-1464. doi: 10.1111/pace.14870. Epub 2023 Nov 13.

    PubMed 37957879

Questions about this trial

What is this clinical trial studying?

A study testing Micra Transcatheter Pacing System (TPS° and Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR in people with Pacing-Induced Cardiomyopathy, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment and comparison of the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function. (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06100757, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in